First-line combination treatment for advanced natural killer/T-cell lymphoma
Part of Cancer clinical trials.
This study tests a new combination of three drugs (golidocitinib, pegaspargase, and an immune checkpoint inhibitor) as the first treatment for advanced extranodal natural killer/T-cell lymphoma. The goal is to see if this combination can shrink or eliminate the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of extranodal natural killer/T-cell lymphoma (a type of lymphoma that usually starts in the nose or throat).
- You must not have received any prior treatment for this lymphoma.
- You must have at least one measurable or visible sign of the disease on a scan.
- You must be generally active and able to care for yourself (ECOG 0-2).
- You must not have serious heart, lung, or liver problems, or active infections like hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
This trial compares two treatment combos for newly diagnosed, advanced NKTCL. It tests a new combination (chidamide plus an immunotherapy drug and pegaspargase) against a standard regimen (DDGP) to see which works better and is safe.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial tests a combination of three drugs (selinexor, an anti-PD-1 antibody, and golidocitinib) for patients with relapsed or refractory NKTCL. The goal is to see if this combination can effectively treat the lymphoma and improve outcomes.
Hear when a new NK T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.